Are oxidative stress and nitric oxide signaling biomarkers associated with disease severity in patients with pulmonary hypertension?
Serum ADMA levels may serve as a useful biomarker for evaluating severity and risk stratification in patients with PAH.
The antioxidative potential and NO signaling are impaired in PAH and CTEPH. Increased serum ADMA level is associated with unfavorable pulmonary hemodynamics in PAH patients. Thus, ADMA may be useful in the severity evaluation and risk stratification of PAH.
Zhang et al. (Fri,) studied this question.